Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs - PubMed (original) (raw)
. 1992 Jan 5;267(1):546-54.
Affiliations
- PMID: 1730616
Free article
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs
D Burdick et al. J Biol Chem. 1992.
Free article
Abstract
The amyloid A4 or beta peptide is a major component of extracellular amyloid deposits that are a characteristic feature of Alzheimer's disease. We synthesized a series of peptide analogs of the A4/beta peptide which are progressively longer at their carboxyl termini, including 42- and 39-residue peptides which represent the major forms of the A4/beta peptide in senile plaque and the hereditary cerebral hemorrhage with amyloidosis form, respectively. All peptides tested, beta 1-28 through beta 1-42, formed amyloid-like fibrils and previously unreported thin sheet-like structures which stained with thioflavin T and Congo Red. The solubility of beta 1-42 and shorter peptides was pH and concentration dependent, with a broad insolubility profile in the pH range of 3.5-6.5 and at concentrations above 0.75 mg/ml. Only peptides of 42 residues or longer were significantly insoluble at pH 7.4. beta 1-47 and beta 1-52 peptides are highly insoluble in aqueous media but are soluble at 40 mg/ml in the alpha helix-promoting solvent, 1,1,1,3,3,3-hexafluoro-2-propanol. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that the beta 1-42 peptide migrates as a series of higher molecular mass aggregates whereas shorter peptides migrate as monomers. Aggregation is also dependent on pH, peptide concentration, and time of incubation in aqueous medium. These results indicate that the length of the hydrophobic carboxyl terminus of the A4/beta peptide is important in determining the solubility and aggregation properties of the A4/beta peptide and that acid pH environment, high peptide concentration, and long incubation time would be predicted to be important factors in promoting amyloid deposition.
Similar articles
- Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease.
Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Hilbich C, et al. J Mol Biol. 1991 Mar 5;218(1):149-63. doi: 10.1016/0022-2836(91)90881-6. J Mol Biol. 1991. PMID: 2002499 - Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides.
Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Hilbich C, et al. J Mol Biol. 1992 Nov 20;228(2):460-73. doi: 10.1016/0022-2836(92)90835-8. J Mol Biol. 1992. PMID: 1453457 - Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra.
Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. Barrow CJ, et al. J Mol Biol. 1992 Jun 20;225(4):1075-93. doi: 10.1016/0022-2836(92)90106-t. J Mol Biol. 1992. PMID: 1613791 - Structural determinants of the Alzheimer's amyloid beta-peptide.
Soto C, Brañes MC, Alvarez J, Inestrosa NC. Soto C, et al. J Neurochem. 1994 Oct;63(4):1191-8. doi: 10.1046/j.1471-4159.1994.63041191.x. J Neurochem. 1994. PMID: 7931272 Review. - Alzheimer's beta-amyloid: insights into fibril formation and structure from Congo red binding.
Inouye H, Kirschner DA. Inouye H, et al. Subcell Biochem. 2005;38:203-24. doi: 10.1007/0-387-23226-5_10. Subcell Biochem. 2005. PMID: 15709480 Review.
Cited by
- Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates.
Choi YS, Hou S, Choe LH, Lee KH. Choi YS, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 1;930:129-35. doi: 10.1016/j.jchromb.2013.05.003. Epub 2013 May 10. J Chromatogr B Analyt Technol Biomed Life Sci. 2013. PMID: 23735279 Free PMC article. - The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics.
Kent SA, Spires-Jones TL, Durrant CS. Kent SA, et al. Acta Neuropathol. 2020 Oct;140(4):417-447. doi: 10.1007/s00401-020-02196-w. Epub 2020 Jul 29. Acta Neuropathol. 2020. PMID: 32728795 Free PMC article. Review. - Modeling the Inhibition Kinetics of Curcumin, Orange G, and Resveratrol with Amyloid-β Peptide.
Madhuranthakam CMR, Shakeri A, Rao PPN. Madhuranthakam CMR, et al. ACS Omega. 2021 Mar 19;6(12):8680-8686. doi: 10.1021/acsomega.1c00610. eCollection 2021 Mar 30. ACS Omega. 2021. PMID: 33817530 Free PMC article. - AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer's Disease Therapy.
Azzaz F, Chahinian H, Yahi N, Fantini J, Di Scala C. Azzaz F, et al. Int J Mol Sci. 2023 Jan 16;24(2):1760. doi: 10.3390/ijms24021760. Int J Mol Sci. 2023. PMID: 36675271 Free PMC article. - Novel proline endopeptidase inhibitors do not modify Abeta40/42 formation and degradation by human cells expressing wild-type and swedish mutated beta-amyloid precursor protein.
Petit A, Barelli H, Morain P, Checler F. Petit A, et al. Br J Pharmacol. 2000 Aug;130(7):1613-7. doi: 10.1038/sj.bjp.0703440. Br J Pharmacol. 2000. PMID: 10928965 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical